Cancer - DynamiCure Biotechnology, LLC

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05785754

A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy and in Combination in Patients with Advanced or Metastatic Solid Tumors

Drug

DCSZ11

Condition

Non-squamous NSCLC immunotherapy-naie microsatellite stable-CRC and other solid tumors